Characterization of binding specificity using GST-conjugated mutant huntingtin epitopes in surface plasmon resonance (SPR)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Polyglutamine extension in the coding sequence of mutant huntingtin causes neuronal degeneration associated with the formation of insoluble polyglutamine aggregates in Huntington’s disease (HD). Mutant huntingtin can form aggregates within the nucleus and processes of neurons possibly due to misfolding of the proteins. To better understand the mechanism by which an elongated polygluta-mine causes aggregates, we have developed an in vitro binding assay system of polyglutamine tract from truncated huntingtin. We made GST-HD exon1 fusion proteins which have expanded poly-glutamine epitopes (e.g., 17, 23, 32, 46, 60, 78, 81, and 94 CAG repeats). In the present emergence of new study adjusted nanotechnology on protein chip such as surface plasmon resonance strategy which used to determine the substance which protein binds in drug discovery platform is worth to understand better neurodegenerative diseases (i.e., Alzheimer disease, Parkinson disease and Hun-tington disease) and its pathogenesis along with development of therapeutic measures. Hence, we used strengths of surface plasmon resonance (SPR) technology which is enabled to examine binding specificity and explore targeted molecular epitope using its electron charged wave pattern in HD pathogenesis utilize conjugated mutant epitope of HD protein and its interaction whether wild type GST-HD interacts with mutant GST-HD with maximum binding affinity at pH 6.85. We found that the maximum binding affinity of GST-HD17 with GST-HD81 was higher than the binding affinities of GST-HD17 with other mutant GST-HD constructs. Furthermore, our finding illustrated that the mutant form of GST-HD60 showed a stronger binding to GST-HD23 or GST-HD17 than GST-HD60 or GST-HD81. These results indicate that the binding affinity of mutant huntingtin does not corre-late with the length of polyglutamine. It suggests that the aggregation of an expanded polyglutamine might have easily occurred in the presence of wild type form of huntingtin.
Abstract
Polyglutamine extension in the coding sequence of mutant huntingtin causes neuronal degeneration associated with the formation of insoluble polyglutamine aggregates in Huntington’s disease (HD). Mutant huntingtin can form aggregates within the nucleus and processes of neurons possibly due to misfolding of the proteins. To better understand the mechanism by which an elongated polygluta-mine causes aggregates, we have developed an in vitro binding assay system of polyglutamine tract from truncated huntingtin. We made GST-HD exon1 fusion proteins which have expanded poly-glutamine epitopes (e.g., 17, 23, 32, 46, 60, 78, 81, and 94 CAG repeats). In the present emergence of new study adjusted nanotechnology on protein chip such as surface plasmon resonance strategy which used to determine the substance which protein binds in drug discovery platform is worth to understand better neurodegenerative diseases (i.e., Alzheimer disease, Parkinson disease and Hun-tington disease) and its pathogenesis along with development of therapeutic measures. Hence, we used strengths of surface plasmon resonance (SPR) technology which is enabled to examine binding specificity and explore targeted molecular epitope using its electron charged wave pattern in HD pathogenesis utilize conjugated mutant epitope of HD protein and its interaction whether wild type GST-HD interacts with mutant GST-HD with maximum binding affinity at pH 6.85. We found that the maximum binding affinity of GST-HD17 with GST-HD81 was higher than the binding affinities of GST-HD17 with other mutant GST-HD constructs. Furthermore, our finding illustrated that the mutant form of GST-HD60 showed a stronger binding to GST-HD23 or GST-HD17 than GST-HD60 or GST-HD81. These results indicate that the binding affinity of mutant huntingtin does not corre-late with the length of polyglutamine. It suggests that the aggregation of an expanded polyglutamine might have easily occurred in the presence of wild type form of huntingtin.
참고문헌 (32)
- Bano D, "Neurodegenerative processes in Huntington’s disease", Cell Death Dis, 2(11), pp.e228~ (2011)
- Bhide PG, "Expression of normal and mutant huntingtin in the developing brain", J Neurosci, 16, pp.5523~5535 (1996)
- Burrus CJ, "Striatal Projection Neurons Require Huntingtin for Synaptic Connectivity and Survival", Cell Rep, 30(3), pp.642~657 (2020)
- Busch A, "Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington’s disease", J Biol Chem, 278, pp.41452~41461 (2003)
- Cooper JK, "Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture", Hum Mol Genet, 7, pp.783~790 (1998)
- Dabrowska M, "Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases", Front Neurosci, 12, pp.75~ (2018)
- DiFiglia M, "Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain", Science, 277, pp.1990~1993 (1997)
- Dunah AW, "Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s disease", Science, 296, pp.2238~2243 (2002)
- Hackam AS, "The influence of huntingtin protein size on nuclear localization and cellular toxicity", J Cell Biol, 141, pp.1097~1105 (1998)
- Hackam AS, "In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington’s disease", Hum Mol Genet, 8, pp.25~33 (1999)
- Jana NR, "Polyglutamine length-dependent interaction of Hsp40and Hsp70 family chaperones with truncated Nterminal huntingtin: their role in suppression of aggregation and cellular toxicity", Hum Mol Genet, 9, pp.2009~2018 (2000)
- Kim S, "Polyglutamine protein aggregates are dynamic", Nat Cell Biol, 4, pp.826~831 (2002)
- Koshy BT, "The CAG", polyglutamine tract diseases: gene products and molecular pathogenesis, 1997, pp.7, 927~942
- Li SH, "Interaction of Huntington disease protein with transcriptional activator Sp1", Mol Cell Biol, 22, pp.1277~1287 (2002)
- Li SH, "Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats", Hum Mol Genet, 7, pp.777~782 (1998)
- Li SH, "Huntingtin-protein interactions and the pathogenesis of Huntington’s disease", Trends in Genetics, 20, pp.146~154 (2004)
- Lunkes A, "Properties of polyglutamine expansion in vitro and in a cellular model for Huntington’s disease", Philos Trans R Soc Lond B Biol Sci, 354, pp.1013~1019 (1999)
- Marquette A, "Membrane Interactions Accelerate the Self-Aggregation of Huntingtin Exon 1 Fragments in a Polyglutamine Length-Dependent Manner", Int J Mol Sci, 22(13), pp.6725~ (2021)
- Martin JB, "Huntington’s disease, Pathogenesis and management", N Engl J Med, 315, pp.1267~1276 (1986)
- Martindale D, "Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates", Nat Genet, 18, pp.150~154 (1998)
- Moulder KL, "Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length", J Neurosci, 19, pp.705~715 (1999)
- Narain Y, "A molecular investigation of true dominance in Huntington’s disease", J Med Genet, 36, pp.739~746 (1999)
- Preisinger E, "Evidence for a recruitment and sequestration mechanism in Huntington’s disease", Philos Trans R Soc Lond B Biol Sci, 354, pp.1029~1034 (1999)
- Reddy PH, "Recent advances in understanding the pathogenesis of Huntington’s disease", Trends Neurosci, 22, pp.248~255 (1999)
- Rigamonti D, "Wild-type huntingtin protects from apoptosis upstream of caspase-3", J Neurosci, 20, pp.3705~3713 (2000)
- Rubinsztein DC, "Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats", Am J Hum Genet, 59, pp.16~22 (1996)
- Sharp AH, "Widespread expression of Huntington’s disease gene (IT15) protein product", Neuron, 14, pp.1065~1074 (1995)
- Vonsattel JP, "Neuropathological classification of Huntington’s disease", J Neuropathol Exp Neurol, 44, pp.559~577 (1985)
- Walker FO, "Huntington’s disease", Lancet, 369(9557), pp.218~228 (2007)
- "World Health Organization" (2019)[URL]
- Yang H, "Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is akey pathogenic form", Nat Commun, 11(1), pp.2582~ (2020)
- Zuccato C, "Huntingtin interacts with REST", NRSF to modulate the transcription of NRSE-controlled neuronal genes, 2003, pp.35, 76~83